ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials

Li, Dailong; Yao, Ling; Xu, Lu; Li, Wanqiang; Che, Yuan*武汉大学; 1; y
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries2022-12-2DOI: 10.1097/MD.0000000000032164
14阅读
引用收藏
分享

摘要

Background: Icotinib is the first generation of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) independently developed in China, which has been widely used in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC). The purpose of this study was to systematically evaluate the efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive NSCLC and to provide evidence-based evidence for clinical rational drug use. Methods: Up to September 30, 2022, the databases of PubMed, EMBASE, Cochrane Library, , China National Knowledge Infrastructure, and Wanfang were searched, and the randomized controlled trials (RCTs) of icotinib (experimental group) versus gefitinib or erlotinib (control group) in the treatment of EGFR-positive advanced NSCLC were included. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included literature. Revman5.4 software was used for meta-analysis.Results: A total of 957 patients were included in 12 studies. The results of meta-analysis showed that the objective response rate (ORR) and disease control rate (DCR) of the experimental group were better than those of the control group (relative risk (RR) = 1.29, 95% confidence interval (CI): 1.10-1.50, P = .001; RR = 1.10, 95%CI: 1.02-1.18, P = .01). There was no significant difference in progression-free survival (PFS) and overall survival between the 2 groups (P > .05). The results of stratified analysis showed that icotinib significantly improved the ORR of EGFR-positive advanced NSCLC patients compared with gefitinib (RR = 1.20, 95%CI: 1.01-1.43, P = .03), but had no significant improvement in DCR (RR = 1.08, 95%CI: 0.99-1.16, P = .07). Compared with erlotinib, icotinib significantly improved ORR and DCR (RR = 1.69, 95%CI: 1.17-2.45, P = .005; RR = 1.21, 95%CI: 1.01-1.44, P = .04). In terms of adverse events of drugs, the incidence of nausea and vomiting in the experimental group was significantly lower than that in the control group (P < .05). Conclusion: Icotinib is safer than gefitinib or erlotinib in the treatment of advanced EGFR-positive NSCLC and seems to bring more clinical benefits to patients. However, there is no obvious advantage in improving the survival rate of patients, and long-term follow-up clinical studies are needed to verify its efficacy.

学科与关键词

关键词
erlotinibgefitinibicotinibmeta-analysisnonsmall cell lung cancer
相关
加载中…
  • EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析
    张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
  • Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
    Lu, Shun*; Zhou, Jianying*; Jian, Hong; Wu, Lin; Cheng, Ying; Fan, Yun; Fang, Jian; Chen, Gongyan; Zhang, Zhihong; Lv, Dongqing; Jiang, Liyan; Wu, Rong; Jin, Xiangming; Zhang, Xiaodong; Zhang, Junhong; Xie, Conghua; Sun, Gengyun; Huang, Dongning; Cui, Jiuwei; Guo, Renhua; Han, Zhigang; Chen, Zhendong; Liang, Jin; Zhuang, Wu; Hu, Xingsheng; Zang, Aimin; Zhang, Yi; Cang, Shundong; Lan, Yuanbo; Chen, Xi; Liu, Laiyu; Li, Xingya; Chen, Jun; Ma, Rui; Guo, Yanzhen; Sun, PingLancet Respiratory Medicine, 2023, 11(10): 905-915.被引 6
  • Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs
    Li, Dailong; Li, Wanqiang; Xu, Lu; Che, Yuan; Cheng, Chunlai*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2022, 101(50).
查看全部 →

发表信息

论文状态
公开发表
期刊
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
发表日期
2022-12-02
卷期
第 101 卷, 第 48 期
DOI
10.1097/MD.0000000000032164
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • L

    Li, Dailong (第一作者)

  • Y

    Yao, Ling

    1 · china three gorges univ

查看全部 5 位作者收起作者
  • X

    Xu, Lu

    wuhan univ

  • L

    Li, Wanqiang

    1 · china three gorges univ

  • C

    Che, Yuan (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417